Tailoring Treatment by Stage: Insights From ADAURA for Stage IB to IIIA EGFR-Mutated NSCLC

EP: 1.Clinical Insights on Osimertinib in Frontline Therapy for EGFR-Mutated NSCLC

EP: 2.Optimizing Treatment for Advanced EGFR-Mutated NSCLC: FLAURA2, Toxicity Management, and ctDNA

EP: 3.ADAURA Trial Findings: Outcomes and CNS Involvement in EGFR-Mutated NSCLC

EP: 4.Osimertinib in Resected Stage IB to IIIA NSCLC: Perspectives on Its Use for Less Common EGFR Mutations

Now Viewing

EP: 5.Tailoring Treatment by Stage: Insights From ADAURA for Stage IB to IIIA EGFR-Mutated NSCLC

EP: 6.Targeted ADCs vs Chemotherapy in Heavily Pretreated NSCLC: Clinical Benefits and Challenges

EP: 7.Role of Datopotamab Deruxtecan in Advanced NSCLC: Insights From TROPION-Lung01

EP: 8.Managing Toxicities With TROP2-Directed ADCs in Advanced NSCLC: Best Practices and Management Strategies

EP: 9.Impressions From TROPION-Lung05: Dato-DXd in Heavily Pretreated Advanced NSCLC

EP: 10.Adverse Event Management and Resistance Mechanisms: Key Considerations for Datopotamab Deruxtecan in Advanced NSCLC

EP: 11.Evaluating Response Rates in HERTHENA-Lung01: Insights on HER3-DXd

EP: 12.Integrating HER3-DXd: Clinical Considerations for Future Approval and Implementation in Practice

Video content above is prompted by the following:

• From a safety, tolerability, and quality-of-life perspective, how significant is the ability of a third-generation EGFR TKI to delay the requirement for subsequent therapy in patients with resectable, stage IB to IIIA, EGFR-mutated NSCLC?
• What are some of the inherent postresection risks of later lines of treatment for EGFR-mutated NSCLC that has progressed despite standard of care?
• What is your discussion in patients with stage IB vs IIIA disease?